.png)
1 year ago
5
DealsHealth
27 February 2023, 4:11 pm. 1 minute
Shares of Syneos Health Inc rose 13% after Reuters exclusively reported that the company is making a new effort to sell itself. The effort comes in the wake of a reduced backlog of contracts for providing clinical research to drug developers that led to a plunge in the value of its shares over the past year. Syneos has hired Bank of America Corp and Centerview Partners LLC for financial advice as it embarks on a new round of talks with potential acquirers that may include industry peers and private equity firms.
Market Impact
Syneos shares rose 13% on the news in morning trade to $43.35 a share at the time of reporting.
Article Tags
Topics of Interest: DealsHealth
Type: Reuters Best
Sectors: Business & FinancePharmaceuticals & Healthcare
Regions: Americas
Countries: United States
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Significant National Story
Sign up for email updates
I'd like to receive communications about Reuters resources, events, products, or services.
(Please note you can manage and update your preferences at any time.)
By submitting your details, you are agreeing to receive communications about Reuters resources, events, products, or services. By submitting your details, you are also acknowledging that you have read and understood our: Privacy Statement.By submitting your details, you are agreeing to receive communications about Reuters resources, events, products, or services. By submitting your details, you are also acknowledging that you have read and understood our: Privacy Statement. * required field
By submitting your details, you are agreeing to receive communications about Reuters resources, events, products, or services. By submitting your details, you are also acknowledging that you have read and understood our: Privacy Statement. * required field
Sign up for email updates
I'd like to receive communications about Reuters resources, events, products, or services.
(Please note you can manage and update your preferences at any time.)
By submitting your details, you are agreeing to receive communications about Reuters resources, events, products, or services. By submitting your details, you are also acknowledging that you have read and understood our: Privacy Statement.By submitting your details, you are agreeing to receive communications about Reuters resources, events, products, or services. By submitting your details, you are also acknowledging that you have read and understood our: Privacy Statement. * required field
By submitting your details, you are agreeing to receive communications about Reuters resources, events, products, or services. By submitting your details, you are also acknowledging that you have read and understood our: Privacy Statement. * required field
English (US) ·